Infection Burden High With Myeloma T-Cell Therapies

Published Date: 14 Apr 2026

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Read Full News

Latest News

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

Todays Updates

Europe Must Rethink Medicine Pricing or Risk Losing Investment

Europe will need to rethink how it values and pays for innovative ⁠medicines or risk losing manufacturing investments and clinical trials, the head of Europe's pharmaceutical industry lobby said.

Medicare AI Creates Errors and Delays for Patients, Doctors

Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress.

Is Creatine for Brain Health Worth a Try?

Research on creatine supplementation has moved from the gym to the brain lab, leading neurologist Heidi Moawad to review the data on creatine’s potential for improving cognitive health.

S1 Episode 2: Is Alcohol the Missing Piece in Your MASLD Workup?

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

S1 Episode 1: Can Primary Care Catch MASLD Before Cirrhosis?

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Palbociclib Gains HER2+ Breast Cancer Maintenance Indication

Palbociclib is now the first CDK4/6 inhibitor approved for metastatic disease regardless of HER2 status.

Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC

Mirvetuximab has come up short in the first randomized trial testing an antibody-drug conjugate plus standard carboplatin for patients with platinum-sensitive ovarian cancer.

Todays Updates

Europe Must Rethink Medicine Pricing or Risk Losing Investment

Europe will need to rethink how it values and pays for innovative ⁠medicines or risk losing manufacturing investments and clinical trials, the head of Europe's pharmaceutical industry lobby said.

Medicare AI Creates Errors and Delays for Patients, Doctors

Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress.

Is Creatine for Brain Health Worth a Try?

Research on creatine supplementation has moved from the gym to the brain lab, leading neurologist Heidi Moawad to review the data on creatine’s potential for improving cognitive health.

S1 Episode 2: Is Alcohol the Missing Piece in Your MASLD Workup?

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

S1 Episode 1: Can Primary Care Catch MASLD Before Cirrhosis?

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Palbociclib Gains HER2+ Breast Cancer Maintenance Indication

Palbociclib is now the first CDK4/6 inhibitor approved for metastatic disease regardless of HER2 status.

Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC

Mirvetuximab has come up short in the first randomized trial testing an antibody-drug conjugate plus standard carboplatin for patients with platinum-sensitive ovarian cancer.

Latest News

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

News All Time

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Recommended News For You

Next Day Mood Is Affected by Ability to Recover From Work.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

Infection Burden High With Myeloma T-Cell Therapies

New Gene Therapy Nears EU Nod for Bladder Cancer

Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer

AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI

Does diabetes impact the prognosis of people with colorectal cancer?

Recommended Articles For You

Anion Gap: The Simple Calculation That Reveals Much About Your Health  

Unraveling the Mysteries of Lymphoma: A Journey into the Unknown 

The Benefits and Side Effects of Bortezomib in the Fight Against Cancer  

What Is Carboxyhemoglobin And How Can It Affect Your Health? 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Drug-chemo combo increases cancer treatment efficacy

2.

June 20, 2023, Health Bulletin No. 12.

3.

Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

4.

The response of bipolar patients to lithium may be predicted by ancestry.

5.

What is a "cancer vaccine" and is it the same as a COVID vaccine?

1.

Understanding Dasatinib: A Promising Drug for Cancer Treatment 

2.

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care

3.

Anemia Symptoms: What You Need to Know 

4.

Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics

5.

Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

2.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

4.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot